Acemini 2024 latest price

Asciminib (scemblix/asciminib) is a kinase inhibitor used to treat adult patients with the following:Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) is in the chronic phase (CP) and has been treated with two or more tyrosine kinase inhibitors (TKIs). and T315Imutated chronic myelogenous leukemiaPh+chronic myelogenous leukemia.

Aximini was launched in the United States in January 2021 and has not yet been launched in China. AssiminiThis drug is produced in Laos, and the officially marketed version has government approval. The retail price of Lucius Pharmaceuticals in Laos40mg60tablets4 is more than one thousand. Recommended doses in Ph+CML CP: 80 mg orally once daily or 40 mg orally twice daily. T315ImutatedCPPh+ CMLRecommended dose:200mg orally twice daily. Avoid eating at least2 hours before and at least 1 hours after taking Asiminib.

The most common adverse reactions with aceminib (≥ 20%) are upper respiratory tract infection, musculoskeletal pain, headache, fatigue, nausea, rash, and diarrhea. The most common laboratory abnormalities (≥ 20%) were decreased platelet count, increased triglycerides, decreased neutrophil count, decreased hemoglobin, increased creatine kinase, increased alanine aminotransferase (ALT), increased lipase, increased amylase, increased aspartate aminotransferase (AST), increased uric acid, and decreased lymphocyte count. If you want to get more high-quality information, you can contact yaode, yaoWe will do our best to help you learn more about high-quality overseas drugs.